Skip to main content
Livermore
Livermore
ZHEN

Yunqi Capital Ltd

SEC CIK
0001912273
Latest filing
Aug 5, 2026

The latest 13F from Yunqi Capital Ltd covers Q2 2026 (filed Aug 5, 2026): 4 long positions worth $124.9M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Staar Surgical Co (STAA) at 74.8%. Livermore has 19 filings on Form 13F from this institution, going back to Q4 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
1
Est. +$13.2M
Added
0
Reduced
1
Est. −$4.15M
Sold out
1
Est. −$3.92M

Top 5 holdings

Share of this quarter's portfolio value

  1. STAAStaar Surgical Co
    74.8%$93.4MHistory
  2. LULufax Holding Ltd
    11.6%$14.5MHistory
  3. PSIXPower Solutions International, Inc.
    10.6%$13.2MHistory
  4. APIAgora, Inc.
    3.1%$3.85MHistory

Share of portfolio

Each position's share of portfolio value

  1. STAA74.8%
  2. LU11.6%
  3. PSIX10.6%
  4. API3.1%

Biggest buys

New and added positions, by estimated amount bought

  1. PSIXPower Solutions International, Inc.
    +$13.2MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. PSIXPower Solutions International, Inc.
    +10.55 pp0.0% → 10.6%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. APIAgora, Inc.
    −$4.15MReducedHistory
  2. PONYPony AI Inc.
    −$3.92MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. APIAgora, Inc.
    −4.60 pp7.7% → 3.1%History
  2. PONYPony AI Inc.
    −4.24 pp4.2% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$124.9M
+$32.5M (+35.2%) vs. prior quarter
Positions
4
0 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
7.4%
Q2 2026, one quarter
Average holding period
11.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.

13F filings by quarter

19 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $170.9M (Q3 2025)

Q4 2021: $133.0MQ1 2022: $86.8MQ2 2022: $115.4MQ3 2022: $91.3MQ4 2022: $148.0MQ1 2023: $158.2MQ2 2023: $136.9MQ3 2023: $130.0MQ4 2023: $142.5MQ1 2024: $144.6MQ2 2024: $158.1MQ3 2024: $159.3MQ4 2024: $156.5MQ1 2025: $101.6MQ2 2025: $140.1MQ3 2025: $170.9MQ4 2025: $125.4MQ1 2026: $92.4MQ2 2026: $124.9M
Q4 2021Q2 2026
13F filings of Yunqi Capital Ltd by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 5, 20264$124.9MSTAALUPSIXvs. Q1 2026SEC
Q1 2026May 11, 20264$92.4MSTAALUAPIvs. Q4 2025SEC
Q4 2025Feb 10, 20266$125.4MSTAALUPDDvs. Q3 2025SEC
Q3 2025Nov 21, 20256$170.9MSTAALUQFINvs. Q2 2025SEC
Q2 2025Aug 7, 20255$140.1MQFINSTAALUvs. Q1 2025SEC
Q1 2025Apr 30, 20254$101.6MSTAAQFINLUvs. Q4 2024SEC
Q4 2024Feb 7, 20255$156.5MJOYYQFINSTAAvs. Q3 2024SEC
Q3 2024Nov 12, 20245$159.3MQFINYMMJOYYvs. Q2 2024SEC
Q2 2024Aug 6, 20248$158.1MQFINYMMJOYYvs. Q1 2024SEC
Q1 2024May 10, 20245$144.6MQFINLUYMMvs. Q4 2023SEC
Q4 2023Feb 2, 20248$142.5MQFINVIPSJOYYvs. Q3 2023SEC
Q3 2023Nov 9, 20236$130.0MQFINJOYYVIPSvs. Q2 2023SEC
Q2 2023Aug 3, 20237$136.9MQFINLUJOYYvs. Q1 2023SEC
Q1 2023May 12, 20236$158.2MQFINBABALUvs. Q4 2022SEC
Q4 2022Feb 3, 20237$148.0MQFINBABATALvs. Q3 2022SEC
Q3 2022Oct 31, 20223$91.3MQFINBABATALvs. Q2 2022SEC
Q2 2022Aug 11, 20225$115.4MQFINBABATALvs. Q1 2022SEC
Q1 2022May 9, 20224$86.8MQFINTALBABAvs. Q4 2021SEC
Q4 2021Feb 22, 20226$133.0MQFINNew Frontier Health CorpBABA–SEC

13D and 13G filings

Companies where Yunqi Capital Ltd reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Yunqi Capital Ltd owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
STAAStaar Surgical Co13D/A6.50%3.26M shares0.00 ppfrom 6.50%Sep 22, 20258 filingsJan 16, 2026SEC

Latest filings

8 filings on file made by Yunqi Capital Ltd or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Yunqi Capital Ltd
CompanyFiled (ET)FormStakeChangeEvent dateFiling
STAAStaar Surgical CoJan 16, 20268:03 PM ET13D/A6.50%3.26M shares0.00 ppfrom 6.50%Jan 14, 2026SEC
STAAStaar Surgical CoJan 8, 20261:05 PM ET13D/A6.50%3.26M shares+1.40 ppfrom 5.10%Jan 6, 2026SEC
STAAStaar Surgical CoDec 11, 20257:00 AM ET13D/A5.10%2.50M shares0.00 ppfrom 5.10%Dec 10, 2025SEC
STAAStaar Surgical CoNov 3, 20256:20 AM ET13D/A5.10%2.50M shares0.00 ppfrom 5.10%Oct 31, 2025SEC
STAAStaar Surgical CoOct 27, 20256:01 AM ET13D/A5.10%2.50M shares0.00 ppfrom 5.10%Oct 25, 2025SEC
STAAStaar Surgical CoOct 21, 20256:04 AM ET13D/A5.10%2.50M shares0.00 ppfrom 5.10%Oct 21, 2025SEC
STAAStaar Surgical CoOct 7, 20256:18 AM ET13D/A5.10%2.50M shares0.00 ppfrom 5.10%Oct 7, 2025SEC
STAAStaar Surgical CoSep 22, 20257:24 AM ET13D5.10%2.50M sharesNewSep 19, 2025SEC